GeoVax to Present COVID-19 Vaccine Breakthroughs at Keystone Symposia

GeoVax Labs, Inc., a clinical-stage biotechnology company, is set to present groundbreaking data from two pivotal studies at the Keystone Symposia on Vaccinology. The presentations will focus on the company's GEO-CM04S1 vaccine candidate and its multi-antigen vaccine technology, demonstrating their ability to induce protective immunity against a range of SARS-CoV-2 variants, from Alpha to Omicron. This development is crucial as it addresses the ongoing challenge of COVID-19 variants and the need for vaccines that can provide broad-spectrum immunity.

The first presentation, led by GeoVax scientist Pratima Kumari, PhD, will detail how MVA-vectored multi-antigen COVID-19 vaccines induce protective immunity against various SARS-CoV-2 variants in preclinical animal models. The second, by Georgia State University scientist Amany Elsharkawy, PhD, will reveal that the GEO-CM04S1 vaccine candidate maintains potent cross-reactivity against the original SARS-CoV-2 B.1 and Omicron subvariant XBB.1.5. These findings underscore the potential of GeoVax's vaccine technology to offer a more effective solution for populations where current vaccines have fallen short, including immunocompromised patients.

Mark Newman, PhD, GeoVax's Chief Scientific Officer, emphasized the importance of inducing broadly specific immune responses, particularly T-cell responses to both the Spike and Nucleocapsid viral proteins. This approach could revolutionize the way vaccines are developed for COVID-19 and other infectious diseases, offering hope for more durable and effective protection against emerging variants. GeoVax's participation in the Keystone Symposia highlights its leadership in the field of vaccinology and its commitment to advancing innovative solutions to global health challenges.